Effect of Spironolactone on CV Function and Fibrosis in People at Increased Risk of Developing Heart Failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Heart Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Effect of Spironolactone on Cardiovascular Function and Markers of Fibrosis in People at Increased Risk of Developing Heart Failure: The Heart 'OMics' in AGEing (HOMAGE) Randomized Clinical Trial
Eur Heart J 2020 Nov 20;[EPub Ahead of Print], JGF Cleland, JP Ferreira, B Mariottoni, P Pellicori, J Cuthbert, JAJ Verdonschot, J Petutschnigg, FZ Ahmed, F Cosmi, HP Brunner La Rocca, MA Mamas, AL Clark, F Edelmann, B Pieske, J Khan, K McDonald, P Rouet, JA Staessen, B Mujaj, A González, J Diez, M Hazebroek, S Heymans, R Latini, S Grojean, A Pizard, N Girerd, P Rossignol, TJ Collier, F ZannadFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.